<DOC>
	<DOCNO>NCT00313560</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Giving erlotinib surgery may make tumor small reduce amount normal tissue need remove . Drugs use chemotherapy , capecitabine gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving erlotinib together combination chemotherapy radiation therapy surgery may kill tumor cell remain surgery . PURPOSE : This randomized phase II trial study well give erlotinib surgery together combination chemotherapy radiation therapy work treat patient stage I stage II pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Erlotinib , Combination Chemotherapy , Radiation Therapy Treating Patients With Stage I Stage II Pancreatic Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pharmacodynamic ( inhibition epidermal growth factor receptor [ EGFR ] activation signal ) effect neoadjuvant erlotinib hydrochloride tumor tissue patient resectable stage I II pancreatic adenocarcinoma . - Determine , preliminarily , antitumor activity ( progression-free survival ) adjuvant erlotinib hydrochloride combination standard chemoradiotherapy comprise capecitabine , gemcitabine hydrochloride , radiotherapy surgical resection patient . Secondary - Characterize toxicity profile adjuvant erlotinib hydrochloride combination standard chemoradiotherapy patient . - Determine pharmacodynamic ( inhibition EGFR activation signal ) effect erlotinib hydrochloride normal tissue ( skin oral mucosa ) patient receive erlotinib hydrochloride adjuvant therapy . - Characterize pharmacokinetics erlotinib hydrochloride ( assess total unbound level ) give combination capecitabine evaluate association common allelic variant candidate gene ( EGFR , TS , DPD , MTHFR , ORM1 ) drug disposition toxicity . - Determine relationship pharmacodynamic effect patient outcome . - Assess value PET/CT scan predictor response erlotinib hydrochloride treatment patient pancreatic cancer . - Evaluate benefit fuse PET/CT scan together radiation treatment plan CT scan . - Determine Active Breathing Coordinator ( ABC ) minimize effect respiratory motion radiation treatment result good radiation coverage tumor bed adjacent lymph node . OUTLINE : This randomize , placebo-controlled study . - Neoadjuvant therapy : Patients randomize 1 2 neoadjuvant treatment arm . - Arm I : Patients receive oral erlotinib hydrochloride day 3-5 day . Patients proceed surgery . - Arm II : Patients receive oral placebo day 3-5 day . Patients proceed surgery . - Surgery : Patients undergo surgical resection . Patients proceed adjuvant therapy . - Adjuvant therapy : Patients receive oral capecitabine twice day oral erlotinib hydrochloride day 5½ week . Patients also undergo concurrent radiotherapy 5 day week 5½ week . Beginning 6 week later , patient receive gemcitabine hydrochloride IV day 1 , 8 , 15 oral erlotinib hydrochloride daily day 1-28 . Treatment gemcitabine hydrochloride erlotinib hydrochloride repeat every 28 day 4 course . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma pancreas Stage I II disease Previously untreated disease Scheduled undergo surgical resection The Johns Hopkins Hospital Candidate postoperative adjuvant chemoradiation PATIENT CHARACTERISTICS : ECOG performance status 01 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 WBC ≥ 3,000/mm^3 AST ALT &lt; 5 time upper limit normal ( ULN ) Bilirubin &lt; 2.0 mg/dL Creatinine &lt; 2.0 mg/dL aPTT &lt; 40 second PT &lt; 2 second ULN Not pregnant nursing Fertile patient must use effective contraception Patients high glucose level ( &gt; 140 mg/dL ) eligible may undergo PET scan first part study No hypersensitivity capecitabine , doxifluridine , fluorouracil No known severe hypersensitivity erlotinib hydrochloride excipients product No coexisting malignancy malignancy diagnose within last 5 year , except basal cell carcinoma cervical cancer situ No ongoing active infection No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No psychiatric illness social situation would limit compliance study requirement No uncontrolled illness No gastrointestinal tract disease result inability take oral medication No known AIDS No evidence clinically active interstitial lung disease Patients chronic stable radiographic change asymptomatic eligible PRIOR CONCURRENT THERAPY : Recovered previous oncologic major surgery No previous radiation abdomen No concurrent phenytoin , carbamazepine , barbiturate , rifampin , phenobarbital , Hypericum perforatum ( St John 's wort ) No concurrent antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
</DOC>